COPD Management and Risk Profiles

Key Differences in Disease Characteristics

The American Thoracic Society notes that cigarette smokers have a higher prevalence of respiratory symptoms, greater annual decline in lung function, and significantly higher COPD mortality compared to non-smokers, but both groups require spirometry-confirmed diagnosis and similar bronchodilator-based management strategies 1
Smokers demonstrate more severe respiratory symptoms, greater lung function abnormalities, and accelerated annual lung function decline compared to never-smokers 2
COPD mortality rates are substantially elevated in smokers versus non-smokers 3
The American College of Chest Physicians recommends that smokers with COPD face increased risk of lung cancer and cardiovascular disease, with approximately 26% of deaths due to cardiovascular causes and 21% due to cancer 4

The American Thoracic Society recommends that spirometry is mandatory for diagnosis in all patients regardless of smoking status, with a diagnostic threshold of post-bronchodilator FEV1/FVC <0.70 confirming persistent airflow limitation 1, 4
Any patient aged 50-70 with dyspnea, chronic cough, sputum production, and/or exposure to risk factors should be suspected of having COPD 1

The American College of Chest Physicians recommends starting with inhaled bronchodilator monotherapy, escalating to combination therapy based on symptom severity and exacerbation risk 4
Aggressively addressing cardiovascular risk factors in both groups is crucial, as they share common pathobiological pathways 4
Long-term oxygen therapy is the only treatment proven to improve prognosis in severe COPD with hypoxemia, with a target oxygen saturation of 88-92% for patients with respiratory acidosis 4

Never-smokers with COPD have increased risk of pneumonia and mortality from respiratory failure, and should be considered for pneumococcal and influenza vaccination as priority preventive measures 3, 5